Amisulpride

CHEMBL243712 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.5 g/mol

LogP

1.5

Phase

4

This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.

Molecular Weight

369.5000 g/mol

LogP

1.50

TPSA

110.00 Å²

Lipinski RO5

Pass

Therapeutic Areas

Alzheimer's Disease Bipolar Disorder Chronic Pain Generalized Anxiety Disorder Major Depressive Disorder Schizophrenia Type 2 Diabetes

Mechanism of Action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC

InChI

InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)

Molecular Formula

C17H27N3O4S

HBD / HBA

2 / 6

Rotatable Bonds

7

Heavy Atoms

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Amisulpride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL243712. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2159. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Amisulpride on PillFYI

Structure

Quick Data

Formula: C17H27N3O4S
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.